CRISPR-Cas12 gene therapy (HuidaGene)

N/A

Report date: 2025/01/26 18:07:59

Base Information

Drug NameCRISPR-Cas12 gene therapy (HuidaGene)
Drug Alias NameCRISPR-Cas12 gene therapy (HuidaGene)
ClassificationVaccines > Application > Prophylactic vaccineSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionHBsAg inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHuidaGene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuidaGene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A